Back to Top
Cosfroviximab Biosimilar - Research Grade
Frequently Bought Together
Loading...
Cosfroviximab Biosimilar - Research Grade
Endotoxin
≤ 1.0 EU/mg as determined by the LAL method
Purity
>90% by SDS-PAGE
Species Reactivity
Human
Target
Zaire Ebola virus
Concentration
>1mg/ml
Isotype
IgG1 - kappa
Host
CHO Cells
Antibodies Against The Same Target
Sequence
https://www.imgt.org/mAb-DB/
Buffer
ICH3002
Shipping Conditions
Blue ice
Background
The Zaire Ebola virus glycoprotein mediates viral entry and is the principal antigen for neutralizing-antibody and filovirus research. Provided as an unconjugated, non-therapeutic analog of cosfroviximab, this human IgG1-kappa recombinant antibody is intended strictly for research use only (RUO). It is formulated with low endotoxin to in vivo-grade standards and manufactured in scalable milligram-to-gram quantities for high-throughput, heavy-usage virology laboratories that require dependable bulk supply. Suitable applications include neutralization and functional assays, glycoprotein-binding characterization, in vitro screening and preclinical Ebola-infection models, all delivered with consistent lot-to-lot performance.
Purification Method
This monoclonal antibody was purified using Protein A
Formulation
Sterile, preservative-free, solution in PBS. BSA and Azide free.
Storage
This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.
Applications
Functional Assays
Application Notes
This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.
Use
Products are for research use only. Not for use in diagnostic or therapeutic procedures.
Delivery Time
3-4 weeks
Faq (q&a)
Q: Is the Cosfroviximab biosimilar available in gram quantities?
A: Yes — it is manufactured in scalable milligram to gram quantities to support bulk and high-throughput preclinical experiments.
Q: Is this research-grade Cosfroviximab biosimilar suitable for in vivo studies?
A: Yes, it is supplied in a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).
Q: What does the Cosfroviximab biosimilar target?
A: It is a non-therapeutic research analog of Cosfroviximab that recognizes and neutralizes Zaire Ebola virus; for research use only.
Write Your Own Review
Is the Cosfroviximab biosimilar available in gram quantities?
Yes — it is manufactured in scalable milligram to gram quantities to support bulk and high-throughput preclinical experiments.
Is this research-grade Cosfroviximab biosimilar suitable for in vivo studies?
Yes, it is supplied in a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).
What does the Cosfroviximab biosimilar target?
It is a non-therapeutic research analog of Cosfroviximab that recognizes and neutralizes Zaire Ebola virus; for research use only.
Who Viewed This Also Viewed
Add recommended extras
-
In Vivo Buffer pH7.2$112.50
